Cu entuziasm și profesionalism, Dr. Dan CĂLUGĂRU a format o echipă bine pregătită, care având la dispoziție tehnică medicală performantă, ajută la rezolvarea problemelor oftalmologice, punând întotdeauna accent pe confortul și siguranța pacienților, oferind servicii oftamologice complete la standarde înalte de calitate, atât prin experiența profesională cât și ca nivel al dotării cu aparatură. Echipa beneficiază de suportul și experiența Prof. Univ. Dr. Mihai Călugăru.
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
May 2018, Volume 256, Issue 5, pp. 1035–1037
Published online: May 1, 2018
Letter to the Editor: Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial
March 2018, Volume 49, Issue 3, p. 160
Published online: March 21, 2018
Re: Khurana et al.: Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study (Ophthalmol Retina. 2017)
March 2018, Volume 2, Issue 3, p. e5–e6
Published online: March 2, 2018
Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy
March 2018, Volume 256, Issue 3, pp. 627–629
Published online: March 1, 2018
Early Response to Intravitreal Dexamethasone Implant Therapy in Diabetic Macular Edema May Predict Visual Outcome
February 2018, Volume 186, p.164–165
Published online: Feb 1, 2018
Comments to: Restoration of photoreceptors in eyes with diabetic macular edema.
January 2018, Volume 28, Issue 1, pp. 132-133
Published online: January 5, 2018
Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy
January 2018, Volume 256, Issue 1, pp. 233–235
Published online: January 3, 2018
Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy
January 2018, Volume 256, Issue 1, pp. 221–223
Published online: January 3, 2018
Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Macular Edema Secondary to Vein Occlusion
December 2017, Volume 184, p.190–191
Published online: December 1, 2017
Comments to: Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal
Nov-Dec 2017, Volume 27, Issue 6, pp. 627 - 800, e175 - e195
Published online: November 13, 2017
Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial
October 2017, Volume 182, p.204–205
Published online: October 2, 2017
High-frequency aflibercept injections in persistent neovascular age-related macular degeneration
October 2017, Volume 255, Issue 10, pp. 2067–2068
Published online: October 1, 2017
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study
October 2017, Volume 255, Issue 10, pp. 2073–2075
Published online: October 1, 2017
Comment on “Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion”
September 2017, Volume 10, Issue 9, p.1481-1482
Published online: September 5, 2017
Comments to: Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results
Jul-Aug 2017, Volume 27, Issue 4, pp. 387 - 512, e129 - e135
Published online: July 25, 2017
Letter to the Editor: Aflibercept For Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab And/Or Bevacizumab May Further Improve Macular Thickness
July 2017, Volume 48, Issue 7, p.528-529
Published online: July 5, 2017
Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
July 2017, Volume 31, Issue 7, p.1112-1113
Published online: July 4, 2017
Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data
July 2017, Volume 255, Issue 7, pp. 1455–1457
Published online: July 1, 2017
Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema
July 2017, Volume 255, Issue 7, pp. 1451–1452
Published online: July 1, 2017
Comments to: Ranibizumab for persistent diabetic macular edema after bevacizumab treatment
May-Jun 2017, Volume 27, Issue 3, pp. 253 - 386, e99 - e128
Published online: May 11, 2017
Comments to: Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization
May-Jun 2017, Volume 27, Issue 3, pp. 253 - 386, e99 - e128
Published online: May 11, 2017
Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study
May 2017, Volume 177, p.235–236
Published online: May 2, 2017
Bun venit!
În clinica noastră se tratează peste 3000 de pacienți anual, număr în permanentă creștere, având în vedere progresul științific și tehnic de care echipa Dr. Călugăru este mereu preocupată.
Echipamentele noaste sunt furnizate de către producători consacrați în domeniu: Alcon (S.U.A), Bausch & Lomb (SUA), Blanco (Germania), Brumaba (Germania), Carl Zeiss Meditec (Germania), Spacelabs (S.U.A), Getinge (Suedia), Tomey (Japonia), Melag (Germania), Nidek (Japonia), Briot (Belgia).
Pentru operațiile de reducere a dioptriilor cu laser excimer (Lasek, Prk) nu este nevoie de analize. Pentru toate celelalte intervenții chirurgicale analizele sunt obligatorii.
Analizele necesare pentru operație:
- Hemoleucograma
- Coagulograma
- Glicemie
- Uree
- VSH
- AST
- ALT
- Bilirubina totală
- HVB
- HVC
- HIV
- Consult cardiologic
- EKG
Pentru a reuși vindecarea unui număr cât mai mare de pacienți echipa Dr. Călugăru colaborează cu mai mulți medici specializați în oftalmologie, opticieni și optometriști, cât și cu medicii de familie din zonele învecinate.